Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Smartphone app vs no/minimal intervention Cardiorespiratory fitness (CF) (mL/kg/min) · adults Mobile health (m‐health) smartphone interventions for adolescents and adults with overweight or obesity (2024) · Cochrane | no estimate extracted | 1 study · 60 participants | Very low |
Smartphone app vs no/minimal intervention Total activity time (TAA) (min/week) · adults Mobile health (m‐health) smartphone interventions for adolescents and adults with overweight or obesity (2024) · Cochrane | no estimate extracted | 1 study · 650 participants | Moderate |
Smartphone app vs no/minimal intervention Body mass index (BMI) (kg/m2) · adults Mobile health (m‐health) smartphone interventions for adolescents and adults with overweight or obesity (2024) · Cochrane | no estimate extracted | 2 studies · 146 participants | Very low |
Smartphone app vs no/minimal intervention Body weight (BW)(kg) · adults Mobile health (m‐health) smartphone interventions for adolescents and adults with overweight or obesity (2024) · Cochrane | no estimate extracted | 3 studies · 441 participants | Moderate |
Smartphone app vs no/minimal intervention Body weight change (BWC) (kg) · adults Mobile health (m‐health) smartphone interventions for adolescents and adults with overweight or obesity (2024) · Cochrane | no estimate extracted | 3 studies · 1044 participants | Low |
Smartphone app vs no/minimal intervention Health‐related quality of life(WHOQOL‐BREF questionnaire, score · adults Mobile health (m‐health) smartphone interventions for adolescents and adults with overweight or obesity (2024) · Cochrane | no estimate extracted | 1 study · 149 participants | Moderate |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | HR 0.64 [0.53, 0.76] | 2 studies · 1443 participants | Moderate |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy Progression‐free survival (at 24 months) · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | HR 0.48 [0.39, 0.58] | 3 studies · 1663 participants | Moderate |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy Quality of life: EORTC 12 monthScale from: 0 to 100 · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | no estimate extracted | 3 studies · 1096 participants | Low |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy On‐study mortality (longest available · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | Risk Ratio 0.72 [0.62, 0.83] | 3 studies · 1644 participants | Moderate |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy Serious adverse events (longest available · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | Risk Ratio 1.18 [1.02, 1.37] | 3 studies · 1644 participants | Moderate |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy Adverse events (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | Risk Ratio 1.01 [0.99, 1.02] | 3 studies · 1644 participants | Moderate |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | Risk Ratio 1.52 [1.3, 1.78] | 3 studies · 1644 participants | Moderate |
Escitalopram vs placebo PTSD severity at 3 months · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | 1 study · 23 participants | Very low |
Hydrocortisone vs placebo Quality of life at 3 months · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | 1 study · 43 participants | Very low |
Escitalopram vs placebo Dropouts due to adverse events at 3 months · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | 1 study · 31 participants | Very low |
Escitalopram vs placebo PTSD rate at 3 months · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | RR 0.59 [0.03, 13.08] | 1 study · 23 participants | Very low |
Escitalopram vs placebo Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | NR | No studies |
Escitalopram vs placebo Quality of life at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo PTSD severity at 3 months · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | 3 studies · 136 participants | Very low |
Hydrocortisone vs placebo Dropouts due to adverse events at 3 months · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | RR 3.19 [0.13, 75.43] | 2 studies · 182 participants | Low |
Hydrocortisone vs placebo PTSD rate at 3 months · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | RR 0.47 [0.09, 2.38] | 3 studies · 136 participants | Very low |
Hydrocortisone vs placebo Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | NR | No studies |
Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care alone Overall survival (absolute effect size estimates based on survival rate at 20 months) (censored observation) · participants with advanced hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | HR 1.19 [0.78, 1.82] | 1 study · 129 participants | Very low |
Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Adverse events considered non‐serious (number of participants) · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 20.13 [1.25, 324] | 1 study · 45 participants | Very low |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation All‐cause mortality · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 0.4 [0.22, 0.73] | 1 study · 86 participants | Low |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Proportion of people with disease progression · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin Overall survival Censored · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 3.06 [0.16, 60.47] | 1 study · 48 participants | Very low |
Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin Proportion of people with disease progression · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 2.4 [0.57, 10.08] | 1 study · 48 participants | Very low |
Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care alone Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 1.42 [0.6, 3.33] | 1 study · 129 participants | Very low |
Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin Adverse events considered non‐serious (number of events) · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | 1 study · 48 participants | Very low |
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Overall survival · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Proportion of people with disease progression · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 0.86 [0.34, 2.16] | 1 study · 46 participants | Very low |
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Adverse events considered non‐serious (number of events) · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
E1B‐deleted (dl1520) adenovirus vs percutaneous ethanol injection Overall survival · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
E1B‐deleted (dl1520) adenovirus vs percutaneous ethanol injection Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
E1B‐deleted (dl1520) adenovirus vs percutaneous ethanol injection Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
E1B‐deleted (dl1520) adenovirus vs percutaneous ethanol injection Proportion of people with disease progression · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 1.33 [0.58, 3.09] | 1 study · 10 participants | Very low |
Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care alone Health‐related quality of life · participants with advanced hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | 1 study · 129 participants | Very low |
E1B‐deleted (dl1520) adenovirus vs percutaneous ethanol injection Adverse events considered non‐serious (number of participants) · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 0.82 [0.49, 1.38] | 1 study · 10 participants | Very low |
Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care alone Proportion of people with disease progression · participants with advanced hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 2.64 [1.29, 5.43] | 1 study · 129 participants | Very low |
Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care alone Adverse events considered non‐serious (number of participants) · participants with advanced hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 2 [1.47, 2.72] | 1 study · 129 participants | Very low |
Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation All‐cause mortality · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | RR 0.39 [0.2, 0.76] | 1 study · 45 participants | Very low |